Chiasma Inc (CHMA) Fundamental Analysis & Valuation
NASDAQ:CHMA
Current stock price
3.76
-0.24 (-6%)
At close:
3.78
+0.02 (+0.53%)
After Hours:
This CHMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CHMA Profitability Analysis
1.1 Basic Checks
- In the past year CHMA has reported negative net income.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.38% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -2408.65% | ||
| PM (TTM) | -2968.35% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. CHMA Health Analysis
2.1 Basic Checks
- There is no outstanding debt for CHMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -3.09, we must say that CHMA is in the distress zone and has some risk of bankruptcy.
- CHMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.09 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- CHMA has a Current Ratio of 7.91. This indicates that CHMA is financially healthy and has no problem in meeting its short term obligations.
- CHMA has a Quick Ratio of 7.08. This indicates that CHMA is financially healthy and has no problem in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.91 | ||
| Quick Ratio | 7.08 |
3. CHMA Growth Analysis
3.1 Past
- The earnings per share for CHMA have decreased strongly by -46.36% in the last year.
EPS 1Y (TTM)-46.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- CHMA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.36% yearly.
- Based on estimates for the next years, CHMA will show a very strong growth in Revenue. The Revenue will grow by 280.08% on average per year.
EPS Next Y12.13%
EPS Next 2Y22.91%
EPS Next 3Y28.31%
EPS Next 5Y15.36%
Revenue Next Year1731.35%
Revenue Next 2Y702.55%
Revenue Next 3Y405.04%
Revenue Next 5Y280.08%
3.3 Evolution
4. CHMA Valuation Analysis
4.1 Price/Earnings Ratio
- CHMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHMA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -1.42 |
4.3 Compensation for Growth
- CHMA's earnings are expected to grow with 28.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.91%
EPS Next 3Y28.31%
5. CHMA Dividend Analysis
5.1 Amount
- No dividends for CHMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHMA Fundamentals: All Metrics, Ratios and Statistics
3.76
-0.24 (-6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)03-03 2022-03-03/amc
Inst Owners0.88%
Inst Owner Change0%
Ins Owners2.83%
Ins Owner Change0%
Market Cap217.68M
Revenue(TTM)3.03M
Net Income(TTM)-89.94M
Analysts80
Price Target9.28 (146.81%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 71.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.47 | ||
| P/tB | N/A | ||
| EV/EBITDA | -1.42 |
EPS(TTM)-1.61
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.05
BVpS1.08
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.38% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -2408.65% | ||
| PM (TTM) | -2968.35% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.91 | ||
| Quick Ratio | 7.08 | ||
| Altman-Z | -3.09 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
EPS Next Y12.13%
EPS Next 2Y22.91%
EPS Next 3Y28.31%
EPS Next 5Y15.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1731.35%
Revenue Next 2Y702.55%
Revenue Next 3Y405.04%
Revenue Next 5Y280.08%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
Chiasma Inc / CHMA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of Chiasma Inc (CHMA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CHMA.
What is the valuation status of Chiasma Inc (CHMA) stock?
ChartMill assigns a valuation rating of 1 / 10 to Chiasma Inc (CHMA). This can be considered as Overvalued.
What is the profitability of CHMA stock?
Chiasma Inc (CHMA) has a profitability rating of 1 / 10.
Is the dividend of Chiasma Inc sustainable?
The dividend rating of Chiasma Inc (CHMA) is 0 / 10 and the dividend payout ratio is 0%.